Generating Antibiotic Incentives Now Act of 2011
Latest action · Oct 19, 2011 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedOct 19, 2011
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Generating Antibiotic Incentives Now Act of 2011 - Amends the Federal Food, Drug, and Cosmetic Act to extend the exclusivity period for a new prescription drug by five years for a drug that the Secretary of Health and Human Services (HHS) determines to be a qualified infectious disease product. Defines "qualified infectious disease product" to mean an antibiotic drug for treating, detecting, preventing, or identifying a qualifying pathogen (certain pathogens that are resistant to antibiotics). Excludes drugs that are: (1) a supplement to a new drug application for which an extension is in effect or has expired; or (2) a subsequent application for a change that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or a modification to the structure of the product that does not result in a change in safety or effectiveness.
Extends such period of exclusivity an additional six months for a sponsor or manufacturer of a qualified infectious disease product that identifies a companion diagnostic test.
Requires the Secretary to give priority review to any drug determined to be a qualified infectious disease product.
Includes qualified infectious disease products as fast track products for which the Secretary shall facilitate development and expedite review.
Directs the Comptroller General to study the need for incentives to encourage the research, development, and marketing of qualified infectious disease biological products.
Requires the Secretary to: (1) review Food and Drug Administration (FDA) guidelines for clinical trials of antibiotic drugs; and (2) revise such guidelines, as appropriate, to reflect developments in scientific and medical information and technology and to ensure clarity regarding the procedures and requirements for approval of an antibiotic drug.
Cosponsors 14
Members who signed on, in the order they did. Signatures ran from Oct 19, 2011 to May 22, 2012; 6 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-TN | Bob Corker | Original | Oct 19, 2011 |
| D-DE | Christopher A. Coons | Original | Oct 19, 2011 |
| R-TN | Lamar Alexander | Original | Oct 19, 2011 |
| D-CO | Michael F. Bennet | Original | Oct 19, 2011 |
| R-UT | Orrin G. Hatch | Original | Oct 19, 2011 |
| D-PA | Robert P. Casey Jr. | Original | Oct 19, 2011 |
| R-KS | Pat Roberts | Oct 31, 2011 | |
| D-MA | John F. Kerry | Feb 9, 2012 | |
| R-GA | Johnny Isakson | Feb 17, 2012 | |
| R-GA | Saxby Chambliss | Feb 17, 2012 | |
| D-MT | Jon Tester | Apr 19, 2012 | |
| D-AK | Mark Begich | Apr 23, 2012 | |
| D-DE | Thomas R. Carper | May 7, 2012 | |
| R-NH | Kelly Ayotte | May 22, 2012 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| Senate | Health, Education, Labor, and Pensions Committee | Referred Oct 19, 2011 |
Actions 2
Everything that happened, newest first.
- Oct 19, 2011Introduced in Senate
- Oct 19, 2011Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
CRS reports 2
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 2
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| R42680 | The Food and Drug Administration Safety and Innovation Act (FDASIA, P.L. 112-144) Archived | Report | Feb 4, 2013 |
| R42564 | FDA User Fees and the Regulation of Drugs, Biologics, and Devices: Comparative Analysis of S. 3187 and H.R. 5651 Archived | Report | Jun 26, 2012 |
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| HR 2182 | Generating Antibiotic Incentives Now Act of 2011 | Identical bill | Jun 16, 2011 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- A bill to provide incentives for the development of qualified infectious disease products.
- Short Titles as Introduced
- Generating Antibiotic Incentives Now Act of 2011
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Administrative law and regulatory procedures
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Government studies and investigations
- Health
- Infectious and parasitic diseases
- Intellectual property
- Medical research
- Medical tests and diagnostic methods
- Prescription drugs
- Research and development
Text 1
Each version as it was printed, newest first.
- Oct 19, 2011Introduced in Senate
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.